Heart Failure Market Size

The global heart failure market size was valued at $7.29 billion in 2024 and is projected to reach $9.34 billion by 2030, growing at a CAGR of 4.2% during the forecast period.

Heart Failure Market Overview

Heart failure is a medical condition characterized by the heart's inability to pump blood effectively to meet the body's demands. This condition can result from various underlying issues such as coronary artery disease, high blood pressure, or previous heart attacks, leading to weakened heart muscles. As the heart's pumping efficiency declines, fluid can accumulate in the lungs, abdomen, or lower extremities, causing symptoms like shortness of breath, fatigue, swelling, and difficulty exercising. Heart failure requires management through medication, lifestyle changes, and sometimes medical procedures to improve symptoms and enhance the heart's function, aiming to maintain a good quality of life for affected individuals.

Heart Failure Market Dynamics

• The heart failure market is expected to witness significant growth in the future due to the rising prevalence of heart failure cases globally, rising technological advancements in the treatment of heart failure, and an increase in the research and drug development for the treatment.

• Additionally, the growing geriatric population, increased risk of cardiovascular diseases, and improved healthcare facilities are the prominent factors driving the growth of the market.

• However, the high cost of treatment, stringent regulatory requirements, and limited access to healthcare in developing regions are restraining the market growth.

• Moreover, government initiatives in spreading awareness about the symptoms of heart failure and an increase in healthcare investments are creating opportunities for market growth.

Impact of COVID-19 on the Heart Failure Market

The COVID-19 pandemic has significantly impacted the heart failure market, presenting both challenges and opportunities. On one hand, disruptions in healthcare systems, restrictions on non-urgent medical procedures, and fears of contracting the virus have led to delays in heart failure diagnosis and treatment, causing a decline in patient visits and hospital admissions. This has particularly affected the management of chronic conditions and increased the risk of disease progression and complications among heart failure patients. On the other hand, the pandemic has accelerated the adoption of telemedicine and remote monitoring technologies, providing opportunities for remote patient management and reducing the burden on healthcare facilities. Moreover, the focus on respiratory health during the pandemic has highlighted the importance of managing comorbidities such as heart failure, driving awareness, and research in this area. Overall, while COVID-19 has posed challenges to the heart failure market, it has also spurred innovation and reshaped healthcare delivery, potentially leading to long-term improvements in patient care and outcomes.

By Type, the Chronic Heart Failure Segment is projected to show a Prominent Growth Rate in the Heart Failure Market

The chronic heart failure segment is projected to show a prominent growth rate in the heart failure market during the forecast period. Chronic heart failure represents a persistent and often progressive condition, affecting a significant portion of the population worldwide. As the population ages and lifestyles become more sedentary, the prevalence of chronic heart failure continues to rise, driving demand for effective management strategies. Furthermore, advancements in medical technology and therapeutic interventions have significantly improved the prognosis and quality of life for individuals living with chronic heart failure, leading to increased demand for these innovative treatments. Additionally, healthcare systems are increasingly focusing on preventative and long-term care approaches, highlighting the importance of comprehensive management for chronic conditions like heart failure. With a growing understanding of the complex pathophysiology of chronic heart failure, there is a greater emphasis on personalized and targeted therapies, further driving demand for tailored treatment options within this segment. Overall, the combination of a rising prevalence, improved therapeutic options, and evolving healthcare paradigms contribute to the substantial demand for heart failure management within the chronic heart failure segment.

By Geography, North America Region Accounts for the Largest Share of the Market Revenue

North America region accounts for the largest share of the market revenue due to the aging population, as the baby boomer generation reaches older ages, increasing the prevalence of heart failure cases. Additionally, lifestyle factors such as sedentary behavior, poor diet, and high-stress levels contribute to the rise in cardiovascular diseases, including heart failure, across the region. North America also boasts advanced healthcare infrastructure and technology, allowing for early detection, diagnosis, and management of heart failure, thus driving demand for related products and services. Moreover, the region's strong economy enables greater access to healthcare services and innovative treatments, further fueling the demand. Additionally, robust research and development activities, coupled with supportive regulatory frameworks, encourage the introduction of novel therapies and devices, attracting investments from pharmaceutical and medical device companies. Overall, these factors converge to create a substantial demand for heart failure management solutions in the North American market.

Key Target Audience:

• Healthcare Providers (Cardiologists, General Practitioners, Nurses)

• Pharmaceutical Companies

• Medical Device Manufacturers

• Patients and Caregivers

• Government and Regulatory Authorities

• Healthcare Payers (Insurance Companies, Medicare, Medicaid)

• Research Institutions and Academia

• Non-Profit Organizations and Advocacy Groups

List of the Key Players Profiled in the Report Includes: 

• Bayer AG

• Johnson and Johnson

• Novartis AG

• AstraZeneca

• Bristol-Myers Squibb

• Boehringer Ingelheim International GmbH

• Cytokinetics

• Eli Lilly and Company

• Jarvik Heart, Inc.

• Amgen Inc.

• Otsuka Pharmaceutical Co., Ltd.

• Tenax Therapeutics

Recent Developments:

• In January 2024, Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio announced the commencement of GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase II trial aimed at evaluating AB-1002 (also referred to as NAN-101) for the treatment of congestive heart failure (CHF). This trial, an adaptive, double-blind, placebo-controlled, randomized, multicenter study, will assess the safety and efficacy of a single intracoronary infusion of AB-1002 in adults diagnosed with non-ischemic cardiomyopathy classified as New York Heart Association (NYHA) Class III Heart Failure and who have maintained medical stability for at least 4 weeks. The progression of AB-1002 into Phase II represents a significant milestone in the advancement of this innovative investigational gene therapy, offering potential benefits to CHF patients with significant unmet medical needs.

Market Segmentation:

The research report includes in-depth coverage of the industry analysis with size, share, and forecast for the below segments: 

Market by, Type:

• Chronic Heart Failure

• Acute Heart Failure

Market by, Therapeutic Drug:

• Aldosterone Antagonist

• Angiotensin Converting Enzyme Inhibitors

• Angiotensin Receptor II Blocker

• Beta - Blockers

• Cardiac Glycosides

• Diuretics

• Phosphodiesterase III Inhibitors

• Renin-Angiotensin Inhibitors

• Sympathomimetic Agents

• Vasodilators

Market by, Distribution Channel:

• Offline

• Online

Market by, End User:

• Retail Pharmacy

• Online Pharmacy

• Hospital Pharmacy

Market by, Geography:

The heart failure market report also analyzes the major geographic regions and countries of the market. The regions and countries covered in the study include:

• North America (The United States, Canada, Mexico), Market Estimates, Forecast & Opportunity Analysis

• Europe (Germany, France, UK, Italy, Spain, Rest of Europe), Market Estimates, Forecast & Opportunity Analysis

• Asia Pacific (China, Japan, India, South Korea, Australia, New Zealand, Rest of Asia Pacific), Market Estimates, Forecast & Opportunity Analysis

• South America (Brazil, Argentina, Chile, Rest of South America), Market Estimates, Forecast & Opportunity Analysis

• Middle East & Africa (UAE, Saudi Arabia, Qatar, Iran, South Africa, Rest of Middle East & Africa), Market Estimates, Forecast & Opportunity Analysis

What Can be Explored with this Research Report:

• Understand the key trends that will drive the market and the challenges it faces in the current market scenario

• Identify growth opportunities

• Porter's five force analysis

• In-depth analysis of market segments, and regions/countries predicted to observe promising growth

• Historical and forecast size of the market in terms of revenue (USD Million)

• Company profiling with key products and solution offerings, key financial information, SWOT analysis, and business strategies adopted